The Best of Lung Cancer Summit is a digital meeting and will be held on Friday, October 30, 2020 from 9:00 AM - 2:05 PM EDT.
Chaired by Dr. Barbara Melosky and Dr. Paul Wheatley-Price, this year’s program will take the most significant lung cancer data from the 2020 ASCO, ESMO and World Lung conferences, and put it into context for oncology professionals. Speakers will review the latest research with in-depth analysis and discussion to improve the current standard of lung cancer care.
After taking part in the program, participants will be able to:
1. Describe the current and future availability and application of immunotherapy in the treatment of lung cancer.
2. Understand the latest strategies for managing lung cancer with radiation therapy and/or surgery.
3. Discuss approaches for maximizing outcomes on the standard of care in the management of lung cancer using biomarker testing, targeted therapies and other new targets.
Registration will be complimentary for Healthcare professionals. Industry representatives (both sponsor and non-sponsor) can register by contacting Laura Davidson at email@example.com
Dr. Barbara Melosky, MD, FRCP(C), is a clinical professor of medicine at the University of British Columbia and a medical oncologist at the BC Cancer Center in Vancouver. She graduated from medical school at the University of Manitoba and completed a residency in internal medicine and a fellowship in oncology at the University of British Columbia. Dr. Melosky specializes in thoracic malignancies.
She is Head of the Lung Tumour Group in the province of British Columbia.
Dr. Melosky sits on the Executive Lung Site Committee for the Canadian Cancer Trials Group (CCTG). She has chaired the annual Canadian Lung Cancer Conference, attended by over 375 participants, for the last 20 years. She is proud to have started and built the British Columbia Lung Cancer Biobank, which is actively used for research for all interested.
She is published extensively and is considered a national and international expert on thoracic malignancies.
Dr. Paul Wheatley-Price is a medical oncologist at The Ottawa Hospital, with an academic appointment at the University of Ottawa. His research interests are in thoracic oncology, with an emphasis on systemic therapy in challenging clinical scenarios, and in the rare cancer types mesothelioma and thymoma. He is active in lung cancer advocacy, in June 2016 becoming President of Lung Cancer Canada, a national charity supporting lung cancer patient and caregivers, and promoting advocacy and research. At the Ottawa Hospital he is the clinical lead for lung cancer in the Division of Medical Oncology, and is the Deputy Division head.
For more information, please contact Laura Davidson at firstname.lastname@example.org.
|9:00 a.m. - 9:15 a.m. EDT||Welcome Address by Chairs - Dr. Barbara Melosky & Dr. Paul Wheatley-Price|
|9:15 a.m. - 9:55 a.m. EDT||
Adjuvant Therapy in Resected NSCLC EGFRM+
Dr. Normand Blais - Why We Adore ADAURA
Dr. Barbara Melosky - Pitfalls in ADAURA
|9:55 a.m. - 10:10 a.m. EDT||BREAK|
|10:10 a.m. - 10:40 a.m. EDT||Immunotherapy Debate: What is the Best Treatment for PDL1-negative Patients with Advanced NSCLC? - Dr. Rosalyn Juergens vs. Dr. Stephanie Snow|
|10:40 a.m. - 11:10 a.m. EDT||Current State of Biomarker Testing - Dr. Brandon Sheffield|
|11:10 a.m. - 11:40 a.m. EDT||LUNCH|
|11:40 a.m. - 12:10 p.m. EDT||Surgical Update: Impact of Covid-19 on Lung Cancer Surgery - Dr. Jonathan Spicer|
|12:10 p.m. - 12:40 p.m. EDT||Screening Update - Dr. Renelle Myers|
|12:40 p.m. - 12:55 p.m. EDT||BREAK|
|12:55 p.m. - 1:25 p.m. EDT||SBRT Update - Radiation for limited stage small cell - is it time to standardize Canadian practice? - Dr. Alexander Louie|
|1:25 p.m. - 1:55 p.m. EDT||The future of Immuno-Oncology in SCLC in Canada & update on new therapies - Dr. David Dawe|
|1:55 p.m. - 2:05 p.m. EDT||Closing Remarks by Chairs -Dr. Barbara Melosky & Dr. Paul Wheatley-Price|
For sponsorship-related inquiries, please contact Bernadette Gregoris, Director of Operations at email@example.com.